Osmotica Pharmaceuticals OSMT shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis.
Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs.
Osmotica Pharmaceuticals shares traded up 9.18% to $5.59. The stock has a 52-week high of $9.67 and a 52-week low of $2.81.
Myovant Sciences MYOV shares were trading higher after the company announced a collaboration with Pfizer in which the company will receive a $650-million upfront payment.
Myovant Sciences is a health care company focused on redefining care for women and for men.
Myovant Sciences shares traded up 27.65% to $29.04. The stock has a 52-week high of $30.90 and a 52-week low of $5.98.
Aytu BioScience AYTU shares were trading higher after the company announced the completion of its Healight Ultraviolet safety study for patients with COVID-19.
The company said the next step is to present the data to the FDA.
Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets.
Aytu BioScience shares were up 0.65% to $6.16. The stock has a 52-week high of $29.90 and a 52-week low of 86 cents.
Kinnate Biopharma KNTE shares were trading higher after multiple sell-side firms initiated coverage of the stock with a bullish rating.
Kinnate Biopharma is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
The company's product candidate is KIN002787, a Rapidly Accelerated Fibrosarcoma inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors.
Kinnate Biopharma shares were trading 7.18% higher at $40.73. The stock has a 52-week high of $48.75 and a 52-week low of $34.14.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.